circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer.

EMBO Mol Med · 2025 · PMC12686431 · PMID 41214390

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

showed a trendp = 0.160not close (p > 0.1)

Conversely, CRC patients with higher GAS1 expression showed a trend toward improved overall prognosis (Fig. 7F , 9-month PFS rates for high vs. low: 73.9 vs. 50.0%, p = 0.160).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.